 Fifteen patients will be randomized into three treatment groups of five patients each. The first group will receive a standard drug regimen, based on the 1997 ATS guidelines. The second and third groups, in addition to receiving the standard therapy, will also receive three months of IFNgamma and GM-CSF, respectively. All patients will undergo bronchoscopy with bronchoalveolar lavage BAL at the beginning of the study, after three months, and at six months. 